New research published in Clinical Cancer Research demonstrated a strong association between circulating tumor DNA (ctDNA) changes and treatment outcomes for patients with solid tumor types. This aggregate analysis of eight clinical trials, focusing on advanced non-small cell lung cancer, was supported by Biodesix and utilized Bio-Rad's Droplet Digital™ PCR (ddPCR) technology.
The study underscores the utility of Bio-Rad's ddPCR platform in high-sensitivity applications, such as detecting rare mutations and quantifying viral load. The technology's inherent ability to provide absolute quantification and detect low-abundance targets is a key differentiator in oncology research and patient monitoring.
This publication validates the value of Bio-Rad's ddPCR technology in clinical settings, particularly for minimal residual disease monitoring. It reinforces the platform's role in advancing cancer research and potentially guiding treatment decisions, which is significant for Bio-Rad's market position in molecular diagnostics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.